LONDON--(BUSINESS WIRE)--Jul 26, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat hyperinsulinemia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180726005592/en/
Technavio has published a new report on the drug development pipeline for hyperinsulinemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Hyperinsulinemia: Market overview
Hyperinsulinemia is a condition in which abnormally high levels of insulin circulate in the body. Insulin is a hormone produced by the pancreas to maintain the blood sugar levels in the body. Hyperinsulinemia is associated with metabolic syndromes such as hypertension, obesity, dyslipidemia, and glucose intolerance. Hyperinsulinemia is caused due to insulin resistance, which means, the body does not respond correctly to insulin. Hyperinsulinemia can lead to high blood sugar levels as diabetes progresses, high blood pressure, high cholesterol, and reduced blood fat levels.
According to a senior market research analyst at Technavio, “In adults, hyperinsulinemia is often associated with type 2 diabetes. However, in neonates, congenital hyperinsulinemia can be observed from birth. Congenital hyperinsulinemia is caused by mutations in genes that regulate the release of insulin, which is produced by beta cells in the pancreas. The congenital hyperinsulinemia causes lethargy and irritability in infants and young children. The severity of congenital hyperinsulinemia varies widely among affected individuals, even among members of the same family.”
Hyperinsulinemia: Segmentation analysis
This pipeline analysis report segments the hyperinsulinemia market based on RoA (oral, parenteral, intravenous, subcutaneous, and subcutaneous/intravenous), therapeutic modality (small molecule, monoclonal antibody, biological, and peptide), geographical segmentation (the US and the UK) and recruitment status (completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 29% of the molecules that are being investigated for the treatment of hyperinsulinemia are small molecule.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180726005592/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH DIABETES SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/26/2018 10:34 AM/DISC: 07/26/2018 10:34 AM